[Dipromonium in the treatment of scleroderma patients].
Basing on the literature data on dipromonium biochemical and pharmacologic characteristics and on her own experience, the author has developed the treatment schemes with due consideration for scleroderma severity. The treatment has been associated with a reduction of glycosaminoglycan excretion with the urine, this correlating with the clinical improvement resultant from dipromonium therapy.
Khamaganova
I V
IV
D000293:Adolescent; D000328:Adult; D000368:Aged; D002331:Carnitine / Q000627:therapeutic use; D002908:Chronic Disease; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000644:Quaternary Ammonium Compounds / Q000627:therapeutic use*; D012594:Scleroderma, Localized / Q000188:drug therapy*
D003879:Dermatologic Agents; D000644:Quaternary Ammonium Compounds; C001002:diisopropylamine dichloroacetate; D002331:Carnitine
Dipromoniĭ v lechenii bol'nykh sklerodermieĭ.